These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8584733)

  • 1. [Gene therapy for ornithine transcarbamylase deficiency].
    Matsuda I; Kiwaki K; Komaki S; Hoshide R; Matsuura T; Endo F
    Tanpakushitsu Kakusan Koso; 1995 Dec; 40(17):2759-64. PubMed ID: 8584733
    [No Abstract]   [Full Text] [Related]  

  • 2. [Gene therapy for ornithine transcarbamylase (OTC) deficient mice].
    Shimada T; Saheki T
    Tanpakushitsu Kakusan Koso; 1995 Dec; 40(17):2674-8. PubMed ID: 8584719
    [No Abstract]   [Full Text] [Related]  

  • 3. Vector-related tumorigenesis not found in ornithine transcarbamylase-deficient mice.
    Koeberl DD
    Mol Ther; 2006 Jul; 14(1):1-2. PubMed ID: 16750655
    [No Abstract]   [Full Text] [Related]  

  • 4. Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes.
    Morsy MA; Zhao JZ; Ngo TT; Warman AW; O'Brien WE; Graham FL; Caskey CT
    J Clin Invest; 1996 Feb; 97(3):826-32. PubMed ID: 8609240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy on trial.
    Marshall E
    Science; 2000 May; 288(5468):951-7. PubMed ID: 10841710
    [No Abstract]   [Full Text] [Related]  

  • 6. Virus treatment questioned after gene therapy death.
    Lehrman S
    Nature; 1999 Oct; 401(6753):517-8. PubMed ID: 10524611
    [No Abstract]   [Full Text] [Related]  

  • 7. Gene therapy for ornithine transcarbamylase deficiency.
    Kiwaki K; Matsuda I
    Acta Paediatr Jpn; 1996 Apr; 38(2):189-92. PubMed ID: 8677801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for human liver disease.
    Raper SE; Wilson JM
    Prog Liver Dis; 1995; 13():201-30. PubMed ID: 9224503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.
    Kiwaki K; Kanegae Y; Saito I; Komaki S; Nakamura K; Miyazaki JI; Endo F; Matsuda I
    Hum Gene Ther; 1996 May; 7(7):821-30. PubMed ID: 8860834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver.
    Ginn SL; Cunningham SC; Zheng M; Spinoulas A; Carpenter KH; Alexander IE
    Gene Ther; 2009 Jun; 16(6):820-3. PubMed ID: 19357713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retroviral-mediated gene transfer of human ornithine transcarbamylase into primary hepatocytes of spf and spf-ash mice.
    Grompe M; Jones SN; Loulseged H; Caskey CT
    Hum Gene Ther; 1992 Feb; 3(1):35-44. PubMed ID: 1562638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes.
    Morsy MA; Alford EL; Bett A; Graham FL; Caskey CT
    J Clin Invest; 1993 Sep; 92(3):1580-6. PubMed ID: 8376608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sparse fur mouse as a model for gene therapy in ornithine carbamoyltransferase deficiency.
    Batshaw ML; Yudkoff M; McLaughlin BA; Gorry E; Anegawa NJ; Smith IA; Hyman SL; Robinson MB
    Gene Ther; 1995 Dec; 2(10):743-9. PubMed ID: 8750014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ornithine transcarbamylase gene: new "private" mutations in four patients and study of a polymorphism.
    Tuchman M; Plante RJ; Giguère Y; Lemieux B
    Hum Mutat; 1994; 3(3):318-20. PubMed ID: 8019569
    [No Abstract]   [Full Text] [Related]  

  • 15. [Gene therapy in muscular dystrophy].
    Takeda S; Nabeshima Y
    Tanpakushitsu Kakusan Koso; 1995 Dec; 40(17):2765-71. PubMed ID: 8584734
    [No Abstract]   [Full Text] [Related]  

  • 16. Cultured fibroblasts as a tool for improvement of molecular analysis in ornithine transcarbamylase (OTC) deficiency.
    Häberle J; Koch HG
    Hum Mutat; 2003 Jun; 21(6):649. PubMed ID: 12754713
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors.
    Moscioni D; Morizono H; McCarter RJ; Stern A; Cabrera-Luque J; Hoang A; Sanmiguel J; Wu D; Bell P; Gao GP; Raper SE; Wilson JM; Batshaw ML
    Mol Ther; 2006 Jul; 14(1):25-33. PubMed ID: 16677864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations and polymorphisms in the human ornithine transcarbamylase gene: mutation update addendum.
    Tuchman M; Plante RJ
    Hum Mutat; 1995; 5(4):293-5. PubMed ID: 7627182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular characterization of a new mutation E122G of human ornithine transcarbamylase gene].
    Gao H; Li W; Yan ZH; Jiang MH; Rui DR; He YS
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Feb; 20(1):19-22. PubMed ID: 12579493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward a molecular understanding of ornithine transcarbamylase deficiency.
    Fox JE; Rosenberg LE
    Adv Neurol; 1988; 48():71-81. PubMed ID: 2891259
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.